
==== Front
Heliyon
Heliyon
Heliyon
2405-8440
Elsevier

S2405-8440(24)12432-2
10.1016/j.heliyon.2024.e36401
e36401
Research Article
Effects of hydrogen-rich water on blood uric acid in patients with hyperuricemia: A randomized placebo-controlled trial
Wu Fenglin ab1
Ma Jun ac1
Xue Junli a
Jiang Xue a
Liu Jinyu b
Zhang Jiashuo ad
Xue Yazhuo yzhxue@126.com
ab⁎⁎⁎
Liu Boyan byliu@sdfmu.edu.cn
a⁎
Qin Shucun scqin@sdfmu.edu.cn
a⁎⁎
a Shandong Provincial Key Medical and Health Laboratory of Hydrogen Biomedical Research & Key Laboratory of Major Diseases and Hydrogen Medical Translational Applications in Universities of Shandong Province, Taishan Institute for Hydrogen Biomedical Research, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, China
b College of Nursing, Shandong First Medical University and Shandong Academy of Medical Sciences, Tai'an, China
c Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
d Taishan Vocational College of Nursing, Tai'an, China
⁎ Corresponding author. byliu@sdfmu.edu.cn
⁎⁎ Corresponding author. scqin@sdfmu.edu.cn
⁎⁎⁎ Corresponding author. Shandong Provincial Key Medical and Health Laboratory of Hydrogen Biomedical Research & Key Laboratory of Major Diseases and Hydrogen Medical Translational Applications in Universities of Shandong Province, Taishan Institute for Hydrogen Biomedical Research, The Second Affiliated Hospital of Shandong First Medical University, Tai'an, China. yzhxue@126.com
1 These authors contributed equally to this work.

15 8 2024
30 8 2024
15 8 2024
10 16 e3640113 3 2024
9 8 2024
14 8 2024
© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Background

Consumption of hydrogen-rich water (HRW) has been shown to have anti-inflammatory and metabolic-modulatory benefits.

Objective

A randomized, placebo-controlled trial was conducted to assess the potential blood uric acid-lowering effects of HRW consumption with different doses (low and high doses) and duration (4 and 8 weeks) in patients with hyperuricemia.

Methods

The Placebo group consumed three bottles of ordinary drinking water (330 mL per bottle), the Low-HRW group consumed two bottles of HRW (330 mL per bottle, H2 ≥ 4.66 mg/L) and a bottle of ordinary water, and the High-HRW group consumed three bottles of HRW daily for 8 weeks. The primary outcome was the blood uric acid levels following different time points (4 and 8 weeks) compared to baseline.

Results

A total of 100 participants completed the entire trial (32 in Placebo, 35 in Low-HRW, and 33 in High-HRW groups). The high-dose of HRW was more effective than low-dose HRW in controlling blood uric acid. Following an 8-week period, the High-HRW group exhibited a significant reduction in blood uric acid levels compared to the baseline (488.2 ± 54.1 μmol/L to 446.8 ± 57.1 μmol/L, P < 0.05).

Conclusion

As a rather safe agent, the prolonged consumption of HRW may be feasible in the management of hyperuricemia.

Clinical trial registration

chictr.org.cn, identifier ChiCTR2200066369.

Keywords

Blood uric acid
Hyperuricemia
Hydrogen-rich water
Dose-effect
Time-effect
==== Body
pmc1 Introduction

Hyperuricemia, a metabolic disorder resulting from impaired purine metabolism, exhibits a higher incidence among middle-aged and elderly males, as well as postmenopausal females. In China, the prevalence of hyperuricemia among adults is estimated to be 14.0 %, including 24.4 % in males and 3.6 % in females, and it continues to increase annually [1,2].

Lifestyle modifications, such as adopting a healthy diet, limiting alcohol consumption, and engaging in regular exercise, have been empirically demonstrated to be efficacious in the prevention and management of hyperuricemia [3,4]. However, when lifestyle modifications cannot achieve the expected effect, specific medications become necessary.

The existing drugs for the treatment of hyperuricemia include uricostatic agents (allopurinol and febuxostat), uricosuric agents (probenecid, benzbromarone, and losartan), and uricolytic agents (plegoticase and rasburicase) [5]. Nevertheless, the majority of these drugs intended to reduce uric acid level are associated with adverse effects, including increased risks of gastrointestinal disorders, cardiovascular diseases, hepatic impairment, and renal dysfunction [5,6]. For instance, allopurinol is a widely used drug of reducing uric acid level, but the occurrence of allopurinol-induced severe cutaneous adverse drug reactions has been reported to range from 3 to 4.68 cases per 1000 new users [6,7]. Consequently, it is imperative to explore a safe and effective supplementary treatment to assist patients in reducing uric acid level while mitigating adverse effects.

Multiple studies have demonstrated a close association between hyperuricemia and oxidative damage caused by reactive oxygen species, and there was a strong correlation between inflammation and uric acid levels across the entire spectrum from hyperuricemia to gout [8,9]. Meanwhile, hyperuricemia has been associated with various diseases including acute and chronic nephropathy, obesity, metabolic syndrome, diabetes, cardiovascular diseases, and hypertension [[10], [11], [12]].

Molecular hydrogen (H2) has been proven to be an anti-oxidative and anti-inflammatory agent [[13], [14], [15]]. Clinical studies have demonstrated that H2 could play a role in the management of obesity, diabetes, cardiovascular diseases, etc [[16], [17], [18], [19], [20]]. These findings imply the potential utility of H2 in the treatment of hyperuricemia.

There are various routes for H2 administration such as H2-rich water (HRW) drinking, H2 gas inhalation, and H2 water bath [21,22]. HRW refers to regular water that contains dissolved H2, and HRW drinking is convenient and extremely bio-safe. A previous randomized placebo-controlled clinical study revealed that a 3-month HRW drinking could exhibit therapeutic benefits in male patients with hyperuricemia [23]. However, the time-effect and dose-effect of HRW are still required for enhanced clinical efficacy.

In this study, we conducted a randomized, placebo-controlled trial to assess the effectiveness of various doses and durations of HRW consumption on patients with hyperuricemia.

2 Materials and methods

2.1 Study design

This study consisted of an 8-week randomized, placebo-controlled, parallel-design trial conducted from May to July 2023. After obtaining informed consent, all participants were randomly allocated to the Placebo group, the Low-HRW group, or the High-HRW group. The intervention was single-blind. The study followed the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) statement for reporting randomized controlled trials. Written informed consent was obtained from all participants. The trial was approved by the Ethical Committee of the Second Affiliated Hospital of Shandong First Medical University (No.2022-122) and was registered at the Chinese Clinical Trial Registry (chictr.org.cn) with the registration number ChiCTR2200066369 (registered on: December 2, 2022). All procedures were carried out in accordance with the Helsinki Declaration.

2.2 Participants

Participants were recruited from Longkou City, Shandong, China. Adult participants with baseline blood uric acid levels >420 μmol/L for males and >360 μmol/L for females were enrolled [24,25]. Exclusion criteria included individuals taking medications that could potentially decrease uric acid levels, those with gout arthritis, with a medical history of severe conditions such as heart failure, malignant tumors, or organ transplant, as well as women during pregnancy or lactating. The criteria for discontinuation encompassed withdrawal of consent, non-compliance, or other medical factors that required the termination of the intervention. Randomized control assignment was performed by an investigator utilizing the R program (1: 1: 1). Each number was placed in a separate, opaque envelope kept by the investigator; each envelope contained the treatment allocation card (experimental group or placebo group). All the investigators knew the assignment and the intervention plan, but the participants did not.

2.3 Intervention

Participants of the Placebo group were instructed to consume three bottles of placebo water (ordinary drinking water with the same appearance as HRW, 330 mL per bottle) daily. The Low-HRW group consumed two bottles of HRW (330 mL per bottle) and one bottle of placebo water daily. The High-HRW group consumed three bottles of HRW daily. The HRW and placebo water are packaged in aluminum cans and supplied by the Beijing Huoliqingyuan Co., Ltd. (Beijing, China). Participants were instructed to consume one bottle of water within 10 min in the morning, noon, and evening, respectively. All participants were instructed to adhere to their regular dietary, pharmaceutical, and lifestyle practices. The H2 concentration of HRW was determined by a Clark-type H2 microsensor (Unisense, Aarhus N, Denmark) in our laboratory by the method previously reported [22], and the H2 concentration was ≥4.66 mg/L. By calculation, the daily H2 intake doses were about 3.08 mg and 4.61 mg in the Low-HRW group and High-HRW group, respectively.

2.4 Outcomes

The primary outcome of this study was the blood uric acid level, and the secondary outcomes included the proportion of participants who achieved a reduction of at least 10 % in blood uric acid after 4 and 8 weeks, as well as the plasma biochemical parameters. The blood uric acid was detected after overnight fasting in participants' fourth finger using a portable uric acid detector (Sannuo Biosensing Co., Ltd., Hunan, China) by a trained technician, and the average of two consecutive measurements was taken. Fasting venous blood samples from median cubital vein were collected into EDTA tubes and subsequently centrifuged (15 min at 1300 g) to obtain plasma. Alkaline phosphatase (ALP), aspartic aminotransferase (AST), alanine aminotransferase (ALT), β2-microglobulin (β2-MG), creatinine (Cr), blood urea nitrogen (BUN), total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and triglyceride (TG) and glucose (GLU) were analyzed by an automatic biochemical analyzer (HITACHI 7080).

2.5 Sample size estimation

The sample size was estimated using the G-Power software, with a 95 % confidence interval, a test power of 85 %, and a 15 % probable drop, and the sample size was calculated to be 114 for three groups.

2.6 Statistical analysis

The data were presented as mean and standard deviation (mean ± SD), median (Quantile 1 and Quantile 3), or percentage. The presence of skewness, outliers, and systematic missing data was evaluated. The normal distribution of the data was assessed using the Shapiro–Wilk test. The blood uric acid levels were analyzed using repeated-measures analysis of variance (ANOVA) followed by Bonferroni's test. The ANOVA, unpaired t-test, and paired t-tests were used to detect inter and intra-group differences in data that adhered to a normal distribution. For data that did not conform to a normal distribution, the Mann-Whitney U test (unpaired) and Wilcoxon signed rank test (paired) were utilized to compare differences. To determine differences between groups of categorical data (eg, proportion with underlying diseases or proportion with ≥10 % decline in blood uric acid), Pearson χ2 test or Fisher exact test were used as applicable. Statistical analyzes were performed by SPSS 26.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered as significantly different in statistics.

3 Results

3.1 Participants

A total of 130 participants agreed to participate in this study, and 114 participants were recruited according to the inclusion and exclusion criteria. These participants were then randomly assigned to the Placebo group (n = 38), the Low-HRW group (n = 38), or the High-HRW group (n = 38). During the follow-up, 6 participants in the Placebo group (One participant was dropped out due to scheduling conflicts and five participants concerned about personal reasons), 3 participants in the Low-HRW group (Three participants were dropped out due to personal reasons), and 5 participants in the High-HRW group (One participant was dropped out due to scheduling conflicts and four participants concerned about personal reasons) withdrew their participation. Finally, a total of 32 participants from the Placebo group, 35 participants from the Low-HRW group, and 33 participants from the High-HRW group successfully completed the 8-week follow-up study (Fig. 1). Upon analysis, it was determined that there were no significant differences in baseline characteristics among the three groups for participants who completed the trial (P > 0.05, Table 1). Furthermore, no adverse effects were reported throughout the entire duration of the study.Fig. 1 Trial flowchart.

Fig. 1

Table 1 Baseline characteristics of participants.

Table 1Characteristics	Placebo group (n = 32)	Low-HRW group (n = 35)	High-HRW group (n = 33)	P	
Male, No. (%)	26 (21.25)	30 (85.71)	27 (81.82)	0.867	
Female, No. (%)	6 (18.75)	5 (14.29)	6 (18.18)	0.867	
Age, years	35.25 ± 8.08	34.23 ± 8.57	35.36 ± 8.75	0.831	
Weight, kg	79.91 ± 16.50	85.23 ± 15.21	83.94 ± 19.78	0.428	
Body mass index	26.72 ± 4.70	28.16 ± 4.57	27.44 ± 4.94	0.466	
SBP, mmHg	125.78 ± 13.16	126.60 ± 21.89	128.63 ± 11.12	0.766	
DBP, mmHg	79.98 ± 9.56	81.26 ± 8.88	79.82 ± 8.76	0.768	
Smoking, n (%)	11 (34.38)	11 (31.43)	10 (30.30)	0.955	
Alcohol drinking, n (%)	8 (25.00)	7 (20.00)	7 (21.21)	0.878	
Uric acid, μmol/L	486.4 ± 71.1	484.8 ± 64.6	488.2 ± 54.1	0.975	
Underlying diseases					
Fatty liver, n (%)	7 (21.88)	5 (14.29)	4 (12.12)	0.531	
Hypertension, n (%)	2 (6.25)	1 (2.86)	2 (6.06)	0.77	
gout, n (%)	0 (0)	1 (2.86)	1 (3.03)	0.618	
Diabetes, n (%)	0 (0)	1 (2.86)	1 (3.03)	0.618	
Age, weight, body mass index, SBP, DBP, and uric acid are presented as the mean ± SD. Intergroup differences were tested by Analysis of Variance (age, weight, body mass index, SBP, DBP, uric acid) or the Kruskall-Wallis test (sex, smoking, alcohol drinking, underlying diseases).

3.2 Blood uric acid

The blood uric acid levels were assessed prior to the intervention, as well as at 4 weeks and 8 weeks following the intervention. As shown in Fig. 2A and Table S1, there were no statistically significant differences in blood uric acid levels between the Placebo and Low-HRW groups at various time points, although a slight but not significant decrease was observed at 8 weeks in the Low-HRW group compared to baseline (P > 0.05). In contrast, the High-HRW group exhibited a tendency towards decreased blood uric acid levels at 4 weeks (P > 0.05), with a significant decrease observed at 8 weeks compared to baseline (488.2 ± 54.1 μmol/L to 446.8 ± 57.1 μmol/L, P < 0.05).Fig. 2 A: Blood uric acid at baseline and after 4 weeks and 8 weeks of intervention; B: Changes in blood uric acid compared to the baseline. Data are represented as the mean ± SD; *P < 0.05 compared to the Baseline.

Fig. 2

The changes in blood uric acid levels are depicted in Fig. 2B and Table S1. After 4 weeks, the average uric acid level in the Low-HRW group exhibited minimal variation compared to the baseline, and it experienced a reduction of 6.74 μmol/L in the High-HRW group. After a period of 8 weeks, the average uric acid level decreased by 19.0 μmol/L in the Low-HRW group and 41.6 μmol/L in the High-HRW group.

We further analyzed the number and percentage of participants with over 10 % decline in blood uric acid level (Table 2). In the Low-HRW group, 7 out of 35 participants (39.4 %) and 13 out of 35 participants (37.1 %) demonstrated a ≥10 % decrease in blood uric acid levels after 4 and 8 weeks, respectively. Meanwhile, in the High-HRW group, 8 out of 33 participants (24.2 %) and 13 out of 33 participants (39.4 %) exhibited a ≥10 % decrease in blood uric acid after 4 and 8 weeks, respectively. There were no significant differences in either the Low-HRW group and the High-HRW group compared to the Placebo group or the Low-HRW group compared to the High-HRW group (P > 0.05).Table 2 Participants exhibiting a reduction of more than 10 % in blood uric acid levels.

Table 2	Placebo group (n = 32)	Low-HRW group (n = 35)	High-HRW group (n = 33)	Pa	Pb	Pc	
4 weeks	3 (9.38 %)	7 (20 %)	8 (24.2 %)	0.38	0.19	0.77	
8 weeks	7 (21.9 %)	13 (37.1 %)	13 (39.4 %)	0.19	0.18	1.00	
Data are presented as numbers (percentages). aLow-HRW group vs. Placebo group. bHigh-HRW group vs. Placebo group. cLow-HRW group vs. High-HRW group.

3.3 Blood assays

Plasma biochemical indicators of all participants were examined before and after the trial. As shown in Table 3, for the liver function indicators, the ALP levels were significantly lower in the Low-HRW group and High-HRW group compared to the baseline after an 8-week intervention, while it displayed a significant increase in the Placebo group. However, no statistically significant differences were observed in the AST and ALT levels among the three groups (P > 0.05).Table 3 Plasma biochemical parameters at baseline and after the 8-week intervention.

Table 3	Placebo group (n = 32)	Low-HRW group (n = 35)	High-HRW group (n = 33)	
Baseline	8 weeks	Baseline	8 weeks	Baseline	8 weeks	
ALP, U/L	78.9 ± 16.2	79.2 ± 17.3*	74.8 ± 20.4	71.9 ± 16.0*	76.4 ± 16.1	75.7 ± 18.7*	
AST, U/L	19.0 (15, 31.3)	21.0 (16.3, 28.8)	19.0 (16.0, 24.0)	21.0 (17.0, 25.5)	21.0 (15.0, 30.5)	22.0 (18.5, 31.0)	
ALT, U/L	29.5 (20.5, 49.3)	29.5 (17.3, 44.8)	30.0 (21.0, 36.0)	29.0 (20.0, 38.0)	26.0 (18.5, 50.0)	27.0 (21.0, 44.0)	
β2-MG, mg/L	1.70 (1.58, 2.00)	1.81 (1.63, 2.09)	1.55 (1.33, 1.94)	1.66 (1.36, 1.84)	1.70 (1.44, 1.87)	1.66 (1.40, 1.85)	
BUN, mmol/L	5.07 ± 0.91	5.29 ± 1.09*	4.91 ± 0.95	5.19 ± 1.16*	4.80 ± 0.76	4.90 ± 1.12*	
Cr, μmol/L	74.5 (66.3, 88.0)	71.6 (63.8, 84.3)	75.0 (67.0, 82.0)	77.2 (72.0, 81.4)	74.0 (65.6, 83.0)	75.1 (66.3, 85.6)	
TC, mmol/L	4.37 (3.83, 5.26)	4.44 (3.98, 5.31)	4.56 (3.91, 5.19)	4.50 (4.01, 4.91)	4.55 (4.09, 5.41)	4.65 (4.34, 5.39)	
LDL-C, mmol/L	2.71 (2.28, 3.34)	2.75 (2.11, 3.15)	2.95 (2.41, 3.30)	2.85 (2.21, 3.11)	2.77 (2.34, 3.31)	2.78 (2.36, 3.18)	
HDL-C, mmol/L	1.09 (0.98, 1.24)	1.02 (0.95, 1.15)*	1.11 (0.96, 1.35)	1.05 (0.94, 1.27)*	1.17 (1.07, 1.37)	1.15 (1.00, 1.30)*	
TG, mmol/L	1.81 (1.18, 2.81)	1.98 (1.04, 2.43)	1.47 (0.99, 2.26)	1.73 (1.08, 2.64)	1.61 (1.05, 2.19)	1.47 (1.10, 2.43)	
GLU, mmol/L	5.09 (4.60, 5.45)	5.33 (5.05, 5.60)*	5.10 (4.79, 5.32)	5.29 (4.99, 5.67)*	5.06 (4.80, 5.29)	5.24 (5.00, 5.47)*	
Data are median (Quantile 1, Quantile 3) or mean ± SD. *P < 0.05 vs. baseline in the same group by paired t-test or Wilcoxon signed rank test.

For the renal function indices, the alterations in β2-MG and Cr did not exhibit statistical significance (P > 0.05) in both the Low-HRW group and High-HRW group. Nevertheless, the levels of BUN demonstrated a significant increase in all three groups after 8 weeks compared to the baseline. The lipid-related indices, including TC, LDL-C, and TG, did not display any statistically significant differences after the 8-week intervention. However, the levels of HDL-C noticeably decreased in all three groups following the intervention. Additionally, the GLU levels exhibited a marked increase in all three groups after the intervention.

4 Discussion

In the current randomized placebo-controlled study, it was observed that an 8 weeks High-HRW intervention resulted in a significant reduction in uric acid levels compared to baseline.

H2 is acknowledged as a relatively safe agent. In the food industry, H2 has obtained official approval as a food additive due to its non-toxic properties [16,26]. A clinical trial has demonstrated that the healthy adults experienced no adverse effects when exposed to 2.4 % H2 gas through inhalation for a duration of up to 72 h [27]. Thus, H2 is well suited for use in adjuvant therapy.

HRW consumption is feasible for daily use. Compared with other H2-supply routes such as inhaling H2 gas, taking a H2-water bath, or stimulating intestinal microbiomes to produce H2, the consumption of bottled HRW ensures an accurate H2-dose. Previous clinical studies have demonstrated the potential benefits of HRW consumption in patients with type 2 diabetes [28], metabolic syndrome [29], unstable angina [17], etc. A six-month study found that the consuming of HRW reduced the level of uric acid in the plasma of healthy rats [30]. Meanwhile, a previous clinical trial assessed that the consumption of HRW could decrease the uric acid levels among individuals with hyperuricemia [23]. However, few studies have been conducted to investigate the time effect and dose effect of H2 intake. In the current study, low and high doses of HRW were employed, and the effects at different times of 4 weeks and 8 weeks were investigated.

The solubility of H2 in water is approximately 1.6 mg/L under standard conditions (20 °C, 101.325 kPa). The utilization of micro and nanobubbles technologies has been shown to enhance the solubility of H2 in water. In the previous clinical studies, the H2 concentrations in HRW varied from 0.4 to 1.6 mg/L [29,31], and it resulting in significant differences in the daily intake of H2. In our current study, the concentration of H2 in HRW was measured as 4.66 mg/L.

The optimal duration for the HRW intervention remains unexplored. For the intervention of metabolic syndrome, the duration of intervention ranging from 8 to 24 weeks [29,32,33], and HRW consuming effectively regulated plasma lipid indices. For patients with non-alcoholic fatty liver disease, HRW intervention durations ranged from 4 to 8 weeks [19,34,35]. In order to assess the intervention effect over time, the current study examined blood uric acid levels after 4 and 8 weeks of HRW consumption. The results of our trial indicate a significant reduction in uric acid levels following an 8-week high-dose HRW intervention. In contrast to pharmacological interventions., the consumption of HRW appears to require a long-term administration for the attainment of clinical efficacy. Considering its remarkable safety profile, HRW is suited as an adjuvant therapy for metabolic disorders.

Hyperuricemia, a metabolic disorder caused by elevated levels of uric acid in the bloodstream due to disrupted purine metabolism, has been found to be associated with inflammatory disorders in previous studies [8,36]. There have studies indicated that the levels of inflammatory markers, including interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1), are markedly elevated in individuals with hyperuricaemia in comparison to those in a healthy state [37]. The levels of IL-6, TNF-α, and TGF-β1 may exacerbate renal tubular and interstitial damage, which may in turn lead to impaired uric acid excretion [37]. Oxidative stress plays a pivotal role in the pathogenesis, progression and regression of hyperuricaemia. Xanthine oxidoreductases (XORs) are pivotal enzymes in uric acid production [38,39]. It has been demonstrated that in humans, XORs may be implicated in the aetiology of metabolic disorders such as hyperuricaemia and metabolic syndrome through oxidative stress, XORs-derived reactive oxygen species, and uric acid-induced inflammatory responses [40,41]. Extensive basic and clinical studies have demonstrated that H2 possesses the capacity to inhibit inflammatory responses, suggesting its potential benefits in the management of hyperuricemia. The potential mechanisms involved in the antioxidant and anti-inflammatory effects of H2 have not yet been completely elucidated. Ohsawa et al. found that H2 selectively reduced hydroxyl radical in cultured cells [13]. Jin et al. proposed that ferroporphyrin may be a biological target of H2, through which hydroxyl radical is reduced into H2O [42]. The mechanisms of HRW consumption on regulating oxidative stress and inflammatory responses, and thereby reducing blood uric acid levels require further inquiry.

Studies have showed a clear relationship of increased uric acid levels with various pathological conditions such as metabolic syndrome, obesity, hypertension, and cardiovascular events [[10], [11], [12]]. Previous clinical studies indicated that consumption of HRW might exert beneficial effect on multiple metabolic diseases. A placebo-controlled trial demonstrated that supplementation with a high-concentration of HRW produced via H2-producing tablets favorably modulated fatty acid and glucose metabolism, and improved inflammation and redox homeostasis in subjects with metabolic syndrome [33]. In patients with type 2 diabetes mellitus, it is noted that supplementation with HRW decreased the levels of oxidized LDL, free fatty acids, and urinary 8-isoprostanes, and may have a beneficial role in the insulin resistance [28]. Another placebo-controlled clinical study suggested that H2 may have potentially beneficial impact on glucose metabolism by modifying the gut microbiota of individuals with impaired fasting glucose [20]. For the regulation of lipid metabolism, it is suggested that HRW have beneficial lipid-lowering effects and can improve high-density lipoprotein function in patients with hypercholesterolemia. Meanwhile, several studies have shown that the consumption of HRW could have advantageous effects on diverse biomarkers for liver function and regulate lipid levels in patients with non-alcoholic fatty liver disease [19,34,43]. The ameliorative effect of HRW on these diseases may play a positive role in the treatment of hyperuricemia.

Our study still has some limitations. Firstly, the duration was relatively short, the long-term beneficial effects of HRW warrant further investigation. Secondly, the daily dietary and physical activity of the participants were not monitored. Thirdly, more biomarkers such as oxidative stress and inflammatory indicators were not addressed in the study. Moreover, due to the limited number of female participants in our study, we were unable to examine the potential impact of HRW on gender-based differences.

5 Conclusion

In conclusion, consumption of HRW at a dose of 330 mL each time and three times daily (totally 4.61 mg H2) for 8 weeks significantly reducing the blood uric acid level in patients with hyperuricemia. It is indicated that a long-term consumption of HRW might exert a beneficial effect in the management of uric acid level.

Ethics statement

The trial was approved by the Ethical Committee of the Second Affiliated Hospital of Shandong First Medical University (No.2022-122) and was registered at the Chinese Clinical Trial Registry (chictr.org.cn) with the registration number ChiCTR2200066369 (registered on: December 2, 2022).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

CRediT authorship contribution statement

Fenglin Wu: Writing – original draft, Investigation, Formal analysis, Data curation. Jun Ma: Writing – original draft, Investigation, Data curation. Junli Xue: Writing – original draft, Investigation. Xue Jiang: Writing – original draft, Investigation. Jinyu Liu: Writing – original draft, Investigation. Jiashuo Zhang: Writing – original draft, Investigation. Yazhuo Xue: Writing – review & editing, Supervision, Investigation, Conceptualization. Boyan Liu: Writing – review & editing, Writing – original draft, Supervision, Investigation, Funding acquisition, Formal analysis, Conceptualization. Shucun Qin: Writing – review & editing, Investigation, Funding acquisition, Conceptualization.

Declaration of competing interest

None.

Appendix A Supplementary data

The following is the supplementary data to this article:Multimedia component 1

Multimedia component 1

Acknowledgements

This research was funded by the 10.13039/501100001809 National Natural Science Foundation of China [82200508 , 81770855 ], Science and Technology Support Plan for Youth Innovation Team of Universities in Shandong Province [2023KJ184 ], and Academic Promotion Programme of 10.13039/501100015507 Shandong First Medical University [2019QL010 ]. The authors thank Beijing Huoliqingyuan Co., Ltd. for providing H2 water.

Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2024.e36401.
==== Refs
References

1 Piao W. Zhao L. Yang Y. The prevalence of hyperuricemia and its correlates among adults in China: results from CNHS 2015-2017 Nutrients 14 19 2022 4095 36235748
2 Zhang M. Zhu X. Wu J. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19 Front. Immunol. 12 2021 791983
3 FitzGerald J.D. Dalbeth N. Mikuls T. American college of rheumatology guideline for the management of gout Arthritis Care Res. 72 6 2020 744 760 2020
4 Sautner J. Eichbauer-Sturm G. Gruber J. Lunzer R. Puchner R. [2022 Update of the Austrian Society for Rheumatology and Rehabilitation nutrition and lifestyle recommendations for patients with gout and hyperuricemia] Z. Rheumatol. 82 1 2023 71 81 36424414
5 Afinogenova Y. Danve A. Neogi T. Update on gout management: what is old and what is new Curr. Opin. Rheumatol. 34 2 2022 118 124 34907116
6 Terkeltaub R. Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review Drugs 83 16 2023 1501 1521 37819612
7 Ng W.L. Lim K.S. Hariraj V. Incidence of allopurinol-induced severe cutaneous adverse drug reaction in Malaysia Br. J. Clin. Pharmacol. 88 8 2022 3782 3788 35318720
8 Li Y. Lin Z. Wang Y. Wu H. Zhang B. Are hyperuricemia and gout different diseases? Comment on the guidelines for the diagnosis and management of hyperuricemia and gout with the healthcare professional perspectives in China Int J Rheum Dis 26 9 2023 1866 1868 36719050
9 Maruhashi T. Hisatome I. Kihara Y. Higashi Y. Hyperuricemia and endothelial function: from molecular background to clinical perspectives Atherosclerosis 278 2018 226 231 30326405
10 Miranda-Aquino T. Pérez-Topete S.E. González-Padilla C. Asymptomatic hyperuricaemia and coronary artery disease Reumatol Clin (Engl Ed). 17 5 2021 263 267 31707094
11 Agnoletti D. Cicero A.F.G. Borghi C. The impact of uric acid and hyperuricemia on cardiovascular and renal systems Cardiol. Clin. 39 3 2021 365 376 34247750
12 Yanai H. Adachi H. Hakoshima M. Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease Int. J. Mol. Sci. 22 17 2021 9221 34502127
13 Ohsawa I. Ishikawa M. Takahashi K. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals Nat. Med. 13 6 2007 688 694 17486089
14 Liu B. Lv P. Zhang X. Zn-Fe primary battery-enabled controlled hydrogen release in stomach for improving insulin resistance in obesity-associated type 2 diabetes Bioact. Mater. 33 2024 242 250 38045569
15 Liu B. Zhao M. Xue J. Gu Q. Zhang X. Qin S. Hydrogen influences HDL-associated enzymes and reduces oxidized phospholipids levels in rats fed with a high-fat diet Life Sci. 267 2021 118945
16 Liu B.Y. Xue J.L. Gu Q.Q. In vivo microelectrode monitoring of real-time hydrogen concentration in different tissues of rats after inhaling hydrogen gas Med. Gas Res. 12 3 2022 107 112 34854421
17 Si Y. Tian H. Dong B. Effects of hydrogen as adjuvant treatment for unstable angina Exp. Biol. Med. 246 18 2021 1981 1989
18 Qin S. Role of hydrogen in atherosclerotic disease: from bench to bedside Curr. Pharmaceut. Des. 27 5 2021 713 722
19 Kura B. Szantova M. LeBaron T.W. Biological effects of hydrogen water on subjects with nafld: a randomized, placebo-controlled trial Antioxidants 11 10 2022 1935 36290657
20 Liang B. Shi L. Du D. Hydrogen-rich water ameliorates metabolic disorder via modifying gut microbiota in impaired fasting glucose patients: a randomized controlled study Antioxidants 12 6 2023 1245 37371975
21 Xue J. Zhao M. Liu Y. Hydrogen inhalation ameliorates hepatic inflammation and modulates gut microbiota in rats with high-fat diet-induced non-alcoholic fatty liver disease Eur. J. Pharmacol. 947 2023 175698
22 Liu B. Xie Y. Chen J. Protective effect of molecular hydrogen following different routes of administration on D-galactose-induced aging mice J. Inflamm. Res. 14 2021 5541 5550 34737603
23 Zheng Y. Han C. Chen Z. Zeng Q. A study on the effect of hydrogen on the hyperuricemia in males Chin. J. Clin. Hepatol. 20 2 2017 118 121 (In Chinese)
24 Sun Y. Sun J. Zhang P. Zhong F. Cai J. Ma A. Association of dietary fiber intake with hyperuricemia in U.S. adults Food Funct. 10 8 2019 4932 4940 31342970
25 Li J.Y. Lee J.I. Lu C.C. Hyperuricemia and its association with osteoporosis in a large asian cohort Nutrients 14 11 2022 2206 35684005
26 Bulut M. Çelebi Sezer Y. Ceylan M.M. Alwazeer D. Koyuncu M. Hydrogen-rich water can reduce the formation of biogenic amines in butter Food Chem. 384 2022 132613
27 Cole A.R. Sperotto F. DiNardo J.A. Safety of prolonged inhalation of hydrogen gas in air in healthy adults Crit Care Explor 3 10 2021 e543 34651133
28 Kajiyama S. Hasegawa G. Asano M. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance Nutr. Res. 28 3 2008 137 143 19083400
29 Song G. Li M. Sang H. Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome J. Lipid Res. 54 7 Jul 2013 1884 1893 23610159
30 Xie F. Jiang X. Yi Y. Different effects of hydrogen-rich water intake and hydrogen gas inhalation on gut microbiome and plasma metabolites of rats in health status Sci. Rep. 12 1 2022 7231 35508571
31 Singh R.B. Halabi G. Fatima G. Rai R.H. Tarnava A.T. LeBaron T.W. Molecular hydrogen as an adjuvant therapy may be associated with increased oxygen saturation and improved exercise tolerance in a COVID-19 patient Clin Case Rep 9 11 2021 e05039
32 Nakao A. Toyoda Y. Sharma P. Evans M. Guthrie N. Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study J. Clin. Biochem. Nutr. 46 2 2010 140 149 20216947
33 LeBaron T.W. Singh R.B. Fatima G. The effects of 24-week, high-concentration hydrogen-rich water on body composition, blood lipid profiles and inflammation biomarkers in men and women with metabolic syndrome: a randomized controlled trial Diabetes Metab Syndr Obes 13 2020 889 896 32273740
34 Korovljev D. Stajer V. Ostojic J. LeBaron T.W. Ostojic S.M. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial Clin Res Hepatol Gastroenterol 43 6 2019 688 693 30982748
35 Sumbalová Z. Kucharská J. Rausová Z. The effect of adjuvant therapy with molecular hydrogen on endogenous coenzyme Q(10) levels and platelet mitochondrial bioenergetics in patients with non-alcoholic fatty liver disease Int. J. Mol. Sci. 24 15 2023 12477
36 Luis-Rodríguez D. Donate-Correa J. Martín-Núñez E. Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia Rheumatology 60 1 2021 371 379 32901294
37 Copur S. Demiray A. Kanbay M. Uric acid in metabolic syndrome: does uric acid have a definitive role? Eur. J. Intern. Med. 103 2022 4 12 35508444
38 Liu N. Xu H. Sun Q. The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors Oxid. Med. Cell. Longev. 2021 2021 1470380
39 Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity Am. J. Physiol. Endocrinol. Metab. 319 5 2020 E827 e834 32893671
40 Battelli M.G. Bortolotti M. Polito L. The role of xanthine oxidoreductase and uric acid in metabolic syndrome Biochim. Biophys. Acta, Mol. Basis Dis. 1864 8 2018 2557 2565 29733945
41 Battelli M.G. Polito L. Bolognesi A. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress Atherosclerosis 237 2 2014 562 567 25463089
42 Jin Z. Zhao P. Gong W. Fe-porphyrin: a redox-related biosensor of hydrogen molecule Nano Res. 16 2 2023 2020 2025
43 Tao G. Zhang G. Chen W. A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease J. Cell Mol. Med. 26 14 2022 4113 4123 35734974
